Which of the following is true regarding monthly opioid antagonist maintenance treatment?

Monthly opioid antagonist maintenance treatment refers to the use of medications, such as naltrexone, administered on a monthly basis to help individuals maintain recovery from opioid use disorder. This approach has been the subject of extensive research, which has demonstrated its effectiveness in reducing opioid cravings and preventing relapse. Numerous studies have shown that when used as part of a comprehensive treatment approach, monthly opioid antagonist therapy can help support patients in their recovery journey.

The evidence gathered from clinical trials and real-world studies validates its utility in various treatment settings, leading to wider implementation by healthcare providers aiming to offer patients effective long-term support. As a result, this treatment modality has gained acceptance as a viable option for managing opioid use disorder, making it a credible and researched aspect of addiction medicine.

The other options do not hold true in the context of established practices for monthly opioid antagonist maintenance treatment. It is not limited to hospital settings, as it can also be provided in outpatient clinics and various community-based treatment centers. The treatment is structured to ensure best practices are followed, rather than being highly unstructured. Moreover, while patients do require monitoring, the frequency is typically less than weekly for those on stable treatment, as the monthly administration of the antagonist allows for more extended periods between evaluations.